Login to Your Account



Clinic Roundup


Monday, June 11, 2012
• Immunomedics Inc., of Morris Plains, N.J., reported data from the ALLEVIATE trials testing epratuzumab, including results from the open-label extension study showing clinically meaningful improvements in health-related quality of life for patients with systemic lupus erythematosus, sustained over two years of treatment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription